Your browser doesn't support javascript.
loading
YTHDC1 as a tumor progression suppressor through modulating FSP1-dependent ferroptosis suppression in lung cancer.
Yuan, Shuai; Xi, Shu; Weng, Hong; Guo, Meng-Meng; Zhang, Jin-Hui; Yu, Zhi-Ping; Zhang, Haozhe; Yu, Zhaojun; Xing, Zengzhen; Liu, Meng-Yang; Ming, Dao-Jing; Sah, Rajiv Kumar; Zhou, Yi; Li, Gang; Zeng, Tao; Hong, Xin; Li, Yafei; Zeng, Xian-Tao; Hu, Hailiang.
Afiliação
  • Yuan S; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Xi S; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Weng H; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Guo MM; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Zhang JH; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Yu ZP; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Zhang H; Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Yu Z; Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Xing Z; Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Liu MY; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Ming DJ; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Sah RK; Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Zhou Y; Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Li G; Cancer Center, Faculty of Health Sciences, MoE Frontier Science Center for Precision Oncology, University of Macau, Taipa, Macau, SAR, China.
  • Zeng T; Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • Hong X; Department of Biochemistry, School of Medicine, Southern University of Science and Technology, Shenzhen, China.
  • Li Y; Key University Laboratory of Metabolism and Health of Guangdong, Southern University of Science and Technology, Shenzhen, China.
  • Zeng XT; Department of Epidemiology, College of Preventive Medicine, Army Medical University, Chongqing, China. liyafei2008@hotmail.com.
  • Hu H; Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China. zengxiantao1128@whu.edu.cn.
Cell Death Differ ; 30(12): 2477-2490, 2023 12.
Article em En | MEDLINE | ID: mdl-37903990
ABSTRACT
Ferroptosis is a regulated cell death process initiated by iron-dependent phospholipid peroxidation and is mainly suppressed by GPX4-dependent and FSP1-dependent surveillance mechanisms. However, how the ferroptosis surveillance system is regulated during cancer development remains largely unknown. Here, we report that the YTHDC1-mediated m6A epigenetic regulation of FSP1 alleviates the FSP1-dependent ferroptosis suppression that partially contributes to the tumor suppressive role of YTHDC1 in lung cancer progression. YTHDC1 knockdown promoted the lung tumor progression and upregulated FSP1 protein level that resulted in ferroptosis resistance of lung cancer cells. Silencing FSP1 abrogated YTHDC1 knockdown-induced proliferation increase and ferroptosis resistance. Mechanistically, YTHDC1 binding to the m6A sites in the FSP1 3'-UTR recruited the alternative polyadenylation regulator CSTF3 to generate a less stable shorter 3'-UTR contained FSP1 mRNA, whereas YTHDC1 downregulation generated the longer 3'-UTR contained FSP1 mRNA that is stabilized by RNA binding protein HuR and thus led to the enhanced FSP1 protein level. Therefore, our findings identify YTHDC1 as a tumor progression suppressor in lung cancer and a ferroptosis regulator through modulating the FSP1 mRNA stability and thus suggest a ferroptosis-related therapeutic option for YTHDC1high lung cancer.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ferroptose / Morte Celular Regulada / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ferroptose / Morte Celular Regulada / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article